Malaria anti-cancer questioned unreliable research team: no response

category:Society click:173
 Malaria anti-cancer questioned unreliable research team: no response


On January 12, Peng Mei News contacted Chen Xiaoping, a professor of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences. The staff refused the request of Peng Mei News to interview Chen Xiaoping. We can accept and understand the doubts and other voices from the outside world, but as a scientific research institution, we hope to do our job well. There is no response at this stage.

The above-mentioned Chen staff told Peng Mei News that at present, all the four hotlines published to the outside world have received public consultation, and some patients have gone to the company (Guangzhou Zhongke Lanhua Biotechnology Co., Ltd.) for consultation. All the work is carried out in an orderly manner, including answering the questions of the volunteers and their families and screening the group.

During the Spring Festival, a speech by Chen Xiaoping, a professor of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, was widely circulated online. He explained the principle of malaria immunotherapy for cancer in popular language. For a time, the news that Plasmodium can cure cancer has become a hot topic in the media platforms.

At the same time, many voices of doubt followed. Professor Wang Liming of the Academy of Life Sciences of Zhejiang University questioned the theoretical basis, clinical data and biological mechanism of Chen Xiaopings research. Wang Liming deduced in his micro-blog article Malaria Anti-cancer, Is It Reliable? that when Chen Xiaoping mentioned that the incidence of malaria and cancer mortality around the world were negatively correlated, he used wrong charts; Chen Xiaopings statistical papers in 2017 could not well support the conclusion that the trend of change of malaria incidence and cancer mortality was opposite over time; Even if there is a slight negative correlation between malaria incidence and cancer mortality, further consideration should be given to the carcinogenicity of malaria and the important interfering factors in the treatment of cancer with antimalarials.

Chen Xiaopings research on anti-cancer of Plasmodium does have a possibility, according to published data, that malaria infection may activate the natural or acquired immune system of the human body, which has a certain killing effect on cancer cells. But that possibility still needs to be dealt with very carefully. Wang Lis inscription also points out.

In response to the above queries, Professor Chen Xiaoping of Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences responded to the news as before by telephone.

The official website of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, shows that Chen Xiaopings team, in cooperation with Academician Zhong Nanshan, has carried out clinical trials of malaria immunotherapy in several hospitals.

On February 8, Academician Zhong Nanshan responded in an interview with CCTV that the therapy was still in the experiment and had not yet reached the stage of being approved for conditional medication. Zhong Nanshan said that the experiment has been carried out for nearly four years, and has been used for the treatment of patients with other treatment methods that are ineffective and whose symptoms are in the terminal stage. At present, nearly 30 cases have been clinically tested and 10 cases have been observed for one year. Among them, 5 cases have obvious effects. These patients mainly suffer from lung cancer, a few from prostate cancer and bowel cancer. He said that there are still many unknowns in the study, there is not enough evidence and enough cases to prove the effectiveness of the method, and individual cases are not enough to illustrate the problem. Now it looks like there are some signs, but its too early to draw a conclusion.

In the clinical trials of Plasmodium, led by Chen Xiaoping, Guangzhou Zhongke Lanhua Biotechnology Co., Ltd. (hereinafter referred to as Zhongke Lanhua) appeared in the sponsors of the trials many times.

The company was founded in early 2013 and invested by the controlling shareholders of the listed company Blue Shield Share. At the beginning of its establishment, the company cooperated with Guangzhou Institute of Biomedicine and Health (GIBH) of Chinese Academy of Sciences. Peng Mei News found that Chen Xiaoping, professor of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, was also the general manager of the company. The companys main technology development is related to malaria. According to the companys official website, the company currently has four original core technologies (3+1). The four technologies are new technologies of malaria immunotherapy for cancer, new therapeutic cancer vaccines with malaria vector, CRR-T cell therapy with malaria protein VAR2CSA as navigation system and a series of them. Related new cancer immunocytotherapy technologies; new antimalarial drug DQ. Source: Wang Zheng_N7526

The company was founded in early 2013 and invested by the controlling shareholders of the listed company Blue Shield Share. At the beginning of its establishment, the company cooperated with Guangzhou Institute of Biomedicine and Health (GIBH) of Chinese Academy of Sciences.

Peng Mei News found that Chen Xiaoping, professor of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, was also the general manager of the company.

The companys main technology development is related to malaria. According to the companys official website, the company currently has four original core technologies (3+1). The four technologies are new technologies of malaria immunotherapy for cancer, new therapeutic cancer vaccines with malaria vector, CRR-T cell therapy with malaria protein VAR2CSA as navigation system and a series of them. Related new cancer immunocytotherapy technologies; new antimalarial drug DQ.